Component Manufacturers Validation Requirements

I recently got asked what a medical device component manufacturer’s validation requirements are. Here is my answer.

Component manufacturers play a crucial role in the medical device industry by producing various parts and components for proper functioning and assembly. Here are some key expectations and responsibilities of component manufacturers in the medical device sector:

Quality and Precision Manufacturing: Medical device components often require high precision, accuracy, and quality to ensure patient safety and device efficacy. To meet these demanding standards, component manufacturers must adhere to stringent quality control measures, utilize advanced manufacturing techniques, and maintain strict tolerances.
Regulatory Compliance: The medical device industry is heavily regulated, and component manufacturers must comply with relevant regulations and standards set by governing bodies like the FDA, ISO, and others. This includes maintaining proper documentation, implementing quality management systems, and ensuring traceability of materials and processes.
Material Selection and Biocompatibility: Many medical device components come into direct contact with the human body or bodily fluids. Consequently, component manufacturers must carefully select biocompatible, non-toxic, and suitable materials for the intended application. They must also ensure proper sterilization and packaging to maintain sterility.
Design and Engineering Support: Some component manufacturers offer design and engineering services in addition to manufacturing to assist medical device companies in developing new components or optimizing existing ones. This collaboration helps ensure that components meet specific performance, functional, and regulatory requirements.
Supply Chain Management: Component manufacturers must have robust supply chain management systems to ensure the timely delivery of components to medical device manufacturers. This includes maintaining adequate inventory levels, managing logistics, and minimizing disruptions in the supply chain.

Yes, component manufacturers in the medical device industry are expected to validate their manufacturing processes to ensure the components they produce meet specified requirements and perform as intended.

Regulatory bodies like the FDA require that components critical to the safety and performance of medical devices be produced through validated processes. This helps ensure that components consistently meet quality standards.
Component manufacturers must perform Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) on their manufacturing equipment and processes.
Validation requirements apply to finished components and raw materials, sub-components received from suppliers, and any processes involved in producing the component. Traceability of validation activities throughout the supply chain is essential.
The level of validation required depends on the component’s criticality and risk to the final medical device. More stringent validation is expected for higher-risk components that directly contact the patient or are essential for device safety and efficacy.
The component manufacturer must maintain validation documentation such as protocols, test reports, and traceability matrices and provide it to the medical device company upon request for review and auditing purposes.

Quality and a Just Culture

It is fascinating that for all the discussion around quality culture, which borrows from Safety II and other safety movements/submovements, we’ve largely avoided using the term justice, which is so prevalent in certain areas of the safety world. One can replace quality with justice and talk about many of the same things.

Both attempt to realize Deming’s Point 8—to drive out fear—which I consider Deming’s most radical proposition.

We really should see them as building blocks. A just culture enables the open reporting and analysis of errors necessary for a quality culture to identify areas for improvement. The two cultures are complementary—a robust quality program requires psychological safety fostered by a just culture. However, a quality culture has broader aims beyond responding to errors or safety lapses. We cannot have a Quality Culture without a Just Culture.

Psychological safety creates an environment where staff can speak up, enabling a just culture. A just culture defines the balanced accountability approach for responding to errors and safety events. A quality culture is a broader concept that drives improvement across the organization, relying on the foundation of a just culture.

But I really wish we used the term justice more. Promoting justice is an activity I wish we took more seriously as a profession.

The State of the Analytical Lifecycle

There have been a lot of changes in the way pharma thinks of analytical lifecycles in the last few years. With changes in technology, new product modalities, ICH Q2(R2) and ICH Q14 being released in November 2023, and USP <1220> in 2022, it is fair to say we are all catching up with our analytical lifecycle programs.

Let’s discuss what I think are the four pivotal documents that provide direction.

ICH Q2(R2) and ICH Q14

ICH Q2(R2) and ICH Q14 are complementary guidelines that provide a comprehensive framework for the development, validation, and lifecycle management of analytical procedures used in the pharmaceutical industry.

ICH Q14 describes the scientific principles and risk-based approaches for developing and maintaining suitable analytical procedures throughout their lifecycle. It outlines the key elements and considerations for analytical procedure development, including:

Defining an Analytical Target Profile (ATP)
Knowledge management and risk assessment
Evaluating robustness and parameter ranges
Establishing an Analytical Procedure Control Strategy
Lifecycle management and post-approval changes
Multivariate analytical procedures
Real-time release testing

On the other hand, ICH Q2(R2) provides specific guidance on validating analytical procedures to demonstrate their suitability for the intended use. It covers various validation tests, methodologies, and evaluation criteria, such as:

Specificity/selectivity
Working range
Accuracy and precision
Robustness
Stability-indicating properties
Multivariate analytical procedures

In summary, ICH Q14 establishes the overarching principles and approaches for analytical procedure development. At the same time, ICH Q2(R2) focuses on the validation aspects to ensure the analytical procedures are fit for purpose and meet quality requirements throughout their lifecycle. The two guidelines are intended to be applied together, with ICH Q14 providing the framework for development and ICH Q2(R2) specifying the validation requirements.

USP <1220> Analytical Procedure Lifecycle and USP <1058> Analytical Instrument Qualification

USP <1220> Analytical Procedure Lifecycle and USP <1058> Analytical Instrument Qualification are closely connected and complementary guidelines that provide a comprehensive framework for ensuring data integrity and quality in analytical procedures throughout their lifecycle.

The key connections between USP <1220> and USP <1058> are:

USP <1220> establishes the principles and requirements for managing the entire lifecycle of analytical procedures, from procedure design and development to retirement. It emphasizes the importance of defining an Analytical Target Profile (ATP) and implementing an Analytical Procedure Control Strategy.
USP <1058> focuses explicitly on the qualification of analytical instruments that execute analytical procedures. It outlines the requirements for ensuring instruments are suitable for their intended use through proper qualification (Design, Installation, Operational, and Performance Qualification).
The instrument qualification activities described in USP <1058> are critical to the overall Analytical Procedure Control Strategy outlined in USP <1220>. Proper instrument qualification as per <1058> helps ensure the quality and integrity of data generated by analytical procedures throughout their lifecycle.
Both guidelines stress the importance of defining user requirements (ATP in <1220> and User Requirements Specification in <1058>) as the basis for procedure development and instrument qualification activities.
USP <1220> requires ongoing monitoring and periodic requalification of analytical procedures, which includes re-evaluating the suitability of the analytical instruments used, as described in the Performance Qualification section of <1058>.

USP <1220> provides the overarching framework for holistically managing analytical procedures. USP <1058> focuses on ensuring the instruments used to execute those procedures are properly qualified and suitable for their intended use. The two guidelines work together to maintain data integrity and quality across the entire analytical lifecycle.

Complementary Approaches

USP <1220> Analytical Procedure Lifecycle is closely related to and complements the ICH Q2(R2) and ICH Q14 guidelines.

USP <1220> aligns with the principles outlined in ICH Q14 for managing the entire lifecycle of analytical procedures, from design and development to retirement. Both emphasize defining an Analytical Target Profile and implementing an Analytical Procedure Control Strategy.
The validation activities described in ICH Q2(R2), such as evaluating specificity, accuracy, precision, and robustness, are critical components of the Analytical Procedure Control Strategy required by USP <1220>.
USP <1220> requires ongoing monitoring and periodic requalification of analytical procedures, which aligns with the lifecycle management approach promoted in ICH Q14 and the validation during the lifecycle section in Q2(R2).
All these guidelines stress the importance of knowledge management, risk management, and a science/risk-based approach throughout the analytical procedure lifecycle.
The instrument qualification requirements outlined in USP <1058> are an integral part of the overall Analytical Procedure Control Strategy described in USP <1220>, ensuring instruments are suitable as per ICH Q2(R2) validation principles.

In essence, USP <1220> provides a comprehensive framework for analytical procedure lifecycle management that incorporates and operationalizes the scientific principles and validation activities detailed in the ICH Q14 and Q2(R2) guidelines, while USP <1058> provides the roadmap for instrument qualification. These four documents establish harmonized best practices for analytical procedures from development through retirement.

Leveraging Inspection Manuals for GMP Inspection Readiness

The various agency inspection manuals are critical tools for inspection readiness. I want to lay out where to find some of these manuals and then go deep into pre-approval inspections, focusing on data integrity.

European Medicines Agency

The European Medicines Agency (EMA) has established detailed procedures and work instructions for coordinating and conducting Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and pharmacovigilance inspections. Here are the key points regarding EMA’s inspection procedures:

GCP Inspection Procedures

EMA identifies applications for GCP inspections based on risk assessment criteria and exchanges information on shared applications with the FDA.
Inspections can be joint (conducted concurrently by EMA and FDA inspectors) or sequential (conducted separately by each agency).
EMA notifies the applicant/marketing authorization holder (MAH) and inspects sites about upcoming inspections through the IRIS industry portal instead of formal letters.
Applicants/MAHs must provide a signed statement accepting the inspection and granting direct access to documents and medical records.
Requested documents should be provided directly to inspectors in electronic format after consulting the reporting inspector.
After the inspection, EMA receives the draft inspection report, finalizes it with the inspectee’s responses, and publishes it in IRIS.

GMP Inspection Procedures

EMA coordinates GMP inspections based on risk assessment for marketing authorization applications, variations, and routine re-inspections.
Work instructions cover areas such as inspection announcement, fee calculation, product sampling/testing, and report circulation.

Pharmacovigilance Inspection Procedures

EMA has specific procedures for coordinating pharmacovigilance inspections and managing non-compliance notifications from MAHs.
Work instructions detail the inspection program creation, data entry in databases, and interactions with third-country inspectorates.

The EMA aims to harmonize inspection processes with the FDA and other regulatory bodies to streamline collaboration and information sharing while ensuring clinical trial subject protection and product quality.

FDA

The FDA Investigations Operations Manual (IOM) is the primary inspection manual used by FDA personnel when performing inspections and investigations.

The key points about the IOM are:

It provides comprehensive instructions, procedures, and policies for FDA investigators and inspectors to follow when conducting inspections, surveys, and investigations.
It covers inspectional activities for foods, drugs, medical devices, biologics, cosmetics, and other FDA-regulated products.
The manual details procedures for inspections of manufacturing facilities, sampling, import operations, recalls, consumer complaints, and other compliance activities.
It aims to ensure inspections are conducted consistently across FDA field offices and provide clear guidance to the industry on the FDA’s inspection approach.
The IOM is updated periodically to incorporate new laws, regulations, policies, and technological changes impacting FDA’s operations.
While not legally binding, the IOM represents the FDA’s current thinking and policies on inspections and investigations.

The FDA Investigations Operations Manual serves as the comprehensive inspection reference and procedure manual for FDA field staff carrying out the agency’s oversight and enforcement activities across all regulated product areas.

Pre-Approval Inspections

For new facilities, CPGM 7346.832, the FDA’s Compliance Program Guidance Manual for Pre-Approval Inspections (PAIs) of drug manufacturing facilities, is critical to spend time with. It outlines the objectives and procedures for FDA inspectors to evaluate a facility’s readiness for commercial manufacturing before approving a new drug application.

The key objectives of CPGM 7346.832 are:

Assess if the facility has a quality system capable of controlling commercial manufacturing operations.
Verify that the manufacturing processes, formulation, and analytical methods conform to the application details.
Audit raw data integrity to authenticate the data submitted in the application.
Evaluate the facility’s commitment to quality in pharmaceutical development (new objective added in 2022 revision).

The guidance instructs inspectors on evaluating the firm’s quality systems, process validation, data integrity, laboratory controls, change management, investigations, batch release procedures, and compliance with current Good Manufacturing Practices (cGMPs). It aims to ensure the facility can reliably produce the drug product described in the application.

Data Integrity

CPGM 7346.832 has specific requirements for data integrity audits during drug manufacturing facility pre-approval inspections (PAIs). Utilizing this document is an excellent way to evaluate your data integrity program.

The key points are:

Objective 3 of the guidance is “Data Integrity Audit”—auditing and verifying raw data associated with the product to authenticate the data submitted in the application.
Inspectors must audit the accuracy and completeness of data reported by the facility for the product. This involves verifying the factual integrity (data matches what was submitted) and contextual integrity (supporting data is complete).
Inspectors should examine raw data, such as chromatograms, analyst notebooks, electronic data, etc., and compare it to the summary data in the application’s Chemistry, Manufacturing, and Controls (CMC) section.
The data integrity audit should focus on finished product stability, dissolution, content uniformity, API impurities, etc.
Inspectors must identify any unreported relevant data, data falsification, improper invalidation of results, or unexplained data discrepancies.
Indications of data integrity issues include altered raw data, references to failing studies, discrepancies between samples, and missing records.

The data integrity audit aims to ensure the CMC data submitted to FDA is complete, reliable, and can be fully authenticated from the raw data at the manufacturing site. Robust data integrity is critical for the FDA to decide on the application’s approval.

Commissioning, Qualification and Validation

Commissioning, qualification, and validation are three distinct but interrelated processes in the pharmaceutical and biotechnology industries that ensure facilities, equipment, systems, and processes meet regulatory requirements and produce products of the desired quality. Here are the key differences:

Commissioning

Commissioning is a systematic process of ensuring that equipment, systems, and facilities are designed, installed, and functioning according to operational and engineering requirements.
It involves design reviews, installation verification, functional testing, and handover to operations.
Commissioning primarily focuses on satisfying engineering requirements and does not have direct regulatory requirements.

Qualification

Qualification is a regulated and documented process that demonstrates that equipment, systems, and facilities are installed correctly and operate as intended for their specific use.
It applies only to equipment, systems, and utilities that directly or indirectly impact product quality and patient safety.
Qualification activities include Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ).
Qualification is focused on by regulatory authorities like the FDA and EMA to ensure compliance.

Validation

Validation is a broader concept establishing documented evidence that a process consistently produces a product that meets its predetermined specifications and quality attributes.
It encompasses the entire process lifecycle, including process design, qualification of equipment/systems, and continued process verification.
Validation ensures that the equipment and systems are qualified and the entire process is controlled to produce the desired final product.

In summary, commissioning verifies engineering requirements, qualification demonstrates suitability for intended use, and validation provides a high degree of assurance that the process will consistently produce a quality product. These activities are interconnected, with commissioning often leveraged during qualification and qualification being a subset of the overall validation process.

FDA’s Framework for Process Validation

The FDA’s Process Validation Guidance is a core document outlining a lifecycle approach with outlines a lifecycle approach with three main stages:

Stage 1: Process Design

Establish a process design based on knowledge gained through development and scale-up activities.
Identify critical quality attributes (CQAs) and critical process parameters (CPPs) using risk assessment and multivariate studies like Design of Experiments (DoE).
Develop a control strategy to ensure CQAs are met.

Stage 2: Process Qualification

Evaluate the process design through facility, utility, and equipment qualification.
Conduct performance qualification (PQ) by running production batches to confirm the process design has reproducible commercial manufacturing.
Establish scientific evidence that the process meets all defined requirements and product specifications.

Stage 3: Continued Process Verification

Maintain the validated status and monitor performance to ensure a state of control.
Identify sources of variation and implement process improvements through an ongoing program.
Conduct product quality reviews periodically to evaluate process performance.

The guidance emphasizes using a science and risk-based approach throughout the lifecycle, leveraging process understanding and knowledge gained from development through commercial production. Effective process validation requires good planning, documented evidence, and a robust quality system.